Answers are grounded in this paper and cite their sources.
Importance Not all men with metastatic castration-sensitive prostate cancer (mCSPC) receive the recommended combination therapy of androgen deprivation therapy (ADT) plus an androgen receptor pathway inhibitor (ARPI) and/or chemotherapy. Objective To determine factors associated with combination therapy use among veterans with mCSPC in the national Veterans Health Administration (VHA) system. Design, Setting, and Participants This cohort study included US veterans diagnosed with mCSPC between January 1, 2023, through December 31, 2024, who were followed up through June 30, 2025. National multicenter data were obtained from the VHA electronic health record, community care settings (private care paid with VHA benefits), and Medicare. All included veterans were identified through a validated natural language processing algorithm, were followed up in the VHA for at least 2 years prior to their metastatic diagnosis, were provided ADT within the first 6 months of diagnosis, and received no prostate cancer–directed therapy in the year prior to diagnosis. Exposure Clinical factors (eg, comorbidities, frailty, prostate cancer burden at diagnosis) and nonclinical factors (eg, annual household income, neighborhood disadvantage) were investigated to determine their association with the outcome. Main Outcomes and Measures The primary outcome was receipt of combination therapy (ie, ADT plus ARPI [abiraterone, enzalutamide, apalutamide, darolutamide] and/or docetaxel) vs ADT alone. Information on these treatments was obtained through pharmacy records. Multilevel logistic regression models were used and marginal predicted probabilities were reported to determine the associations of factors with receipt of combination therapy. Variation among VHA facilities was reported. Results A total of 4023 veterans (mean [SD] age, 75.3 [8.0] years) met eligibility criteria. Of these patients, 2339 (58.1%) had de novo metastatic disease, while 1684 (41.9%) had recurrent disease. Overall, 2564 patients (63.7%) received combination therapy. In adjusted analyses, older veterans (eg, aged 85-89 years: predicted probability, −14.1 [95% CI, −20.5 to −8.2] percentage points [pp]) and veterans with more comorbidities (eg, congestive heart failure: predicted probability, −7.5 [95% CI, −12.9 to −2.5] pp) were less likely to receive combination therapy. Annual household income and neighborhood disadvantage were not associated with receipt of combination therapy. Patients treated by urologists were less likely to receive combination therapy than patients treated by hematologist-oncologists (predicted probability, −23.7 [95% CI, −27.4 to −19.6] pp). Use of combination therapy ranged from 34% to 78% among VHA facilities. Conclusions and Relevance In this cohort study of veterans with de novo and recurrent mCSPC, receipt of combination therapy was high; annual household income and neighborhood disadvantage had no association with treatment use. The study findings suggest that the region where a veteran lives, the facility where they receive care, and the type of cancer specialist they see are factors of the variation in combination therapy use that need further exploration.
No takes yet. Share an insight, caveat, or question.
Caram et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: